Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag vs placebo in lower-risk MDS with platelet transfusion dependence (Japan phase II)
jRCT2021210004Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Eltrombopag with Placebo (2 arms). Primary endpoints: Platelet transfusion independence, Platelet response and 1 more. Started May 2021; status: active, not recruiting.
02
Drugs
eltrombopag
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT2021210004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210004.